Vita 34 AG
ISIN: DE000A0BL849
WKN: A0BL84
31 May 2024 08:33AM

EQS-News: Vita 34 significantly increases earnings and operating cash flow in the first quarter

Vita 34 AG · ISIN: DE000A0BL849 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1914951

EQS-News: Vita 34 AG / Key word(s): Quarterly / Interim Statement
Vita 34 significantly increases earnings and operating cash flow in the first quarter

31.05.2024 / 08:33 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

 

 

Vita 34 significantly increases earnings and operating cash flow in the first quarter

  • Revenues increase by 3.6 percent to EUR 18.6 million
  • EBITDA more than quintuples to EUR 1.5 million
  • Operating cash flow doubles to EUR 4.0 million
  • Outlook for the full year 2024 confirmed

Leipzig, 31 Mai 2024 – Vita 34 AG, the leading cell bank in Europe and the third largest in the world, has made a successful start to the new fiscal year 2024. While the new customer business continues to be challenging against the backdrop of the market environment, business with renewals from existing contracts developed, as expected, much more positively. At the same time, there is a trend towards new customers selecting higher-value product packages.

Revenues amounted to EUR 18.6 million in the reporting period, up 3.6 percent on the previous year (Q1 2023: EUR 17.9 million). The net amount of invoiced services to end consumer business (B2C) increased significantly due to a noticeable rise in demand for contract renewals and, at EUR 18.0 million, was up 13.6 percent on the previous year's level (Q1 2023: EUR 15.9 million). The amount thereof attributable to annually recurring payments totaled EUR 5.7 million (Q1 2023: EUR 5.2 million). "With the start of the new financial year 2024, we have decided to introduce a new key figure in our reporting, which is intended to make our actual corporate development more transparent against the background of the complex accounting in accordance with IFRS 15," explains Jakub Baran, CEO of Vita 34 AG. "The net amount of invoiced services in consumer business (B2C) is intended to give an impression of how our company has developed from a purely operational perspective before the deferral of revenues in accordance with IFRS. We believe the right proportion of annually recurring and prepaying clients is a key factor for the future success of Vita34."

Earnings before interest, taxes, depreciation and amortization (EBITDA) increased significantly year-on-year to EUR 1.5 million (Q1 2023: EUR 0.3 million). In addition to continued cost discipline in the current financial year, the significant percentage increase is mainly due to the special effects that reduced earnings in the same period of the previous year.

"Birth rates in our core markets have remained at a low level so far in 2024," explains CEO Jakub Baran. "However, we have managed to overcompensate for the effect on revenues by increasing prices and encouraging our customers to choose higher-value product packages. In parallel, our location in Dubai, for example, which opened in the fourth quarter of 2023, continues to develop very dynamically."

The key figures for business development are as follows:

  IFRS, in EUR ´000     Q1 Q1  
        2024 2023
  Group revenue          18,557      17,904 3.6%
  Gross profit            6,962        5,681 22.6%
  EBITDA            1,548           272 468.8%
  EBITDA margin [%]               8.3            1.5  
  EBIT     -663 -1,813 63.4%
  Result for the period     -622 -3,040 79.5%
  Earnings per share [in EUR]     -0.05 -0.18 72.2%
  Operating cash flow            3,979        1,974 101.6%
  Cash & cash equivalents
(vs. 31 Dec. 2023)
         15,111      17,416 -13.2%

The company continues to pay particular attention to cost structures in the areas of administration, marketing and sales. Following a decline in sales costs in the first quarter due to slightly weaker than expected new customer business as well as the increased number of contract renewals, operating cash flow improved significantly to EUR 4.0 million in the reporting period. Cash and cash equivalents decreased by EUR 15.1 million compared to the end of 2023, mainly due to the repayment of credit lines. Overall, the high demand for contract renewals in the first quarter is reflected in the Group's continued solid financial position. In view of the as yet unresolved license situation in the new Cell & Gene Therapies and CDMO business areas, investments in these areas continued to be limited in the first quarter of 2024.

In light of the overall business development in line with expectations in the first quarter, the Management Board confirms its outlook for the year as a whole. Accordingly, the Management Board expects revenues of between EUR 81 and 88 million and EBITDA of between EUR 6.5 and 8.0 million for 2024. The forecast is based on a constant exchange rate of the euro against the Polish zloty and other currencies (HUF, RON, TRY, GBP) compared to 29 April 2024.

The Management Board of Vita 34 AG will be available to institutional investors, analysts and representatives of the press on 4 June at 3:00 p.m. in a video conference to provide additional information on business development. Registration for this is by e-mail via the Investor Relations department (ir@vita34.de).

 

Contact:
Vita 34 AG
Investor Relations
Phone: +49 (0341) 48792 – 40
Email: ir@vita34.de

Company Profile

Vita 34 was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. Due to the expansion of the business model following the merger with PBKM, the company intends to invest in the areas of Cell & Gene therapies and CDMO. The body's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with around one million units of stored biological material at Vita 34.

 



31.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1914951

 
End of News EQS News Service

1914951  31.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1914951&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 20,41 19,93 20,07 28,42 68,94 77,06 86,00
EBITDA1,2 4,72 5,43 5,34 0,81 -3,56 5,57 7,40
EBITDA-Margin3 23,13 27,25 26,61 2,85 -5,16 7,23 8,61
EBIT1,4 2,63 2,45 2,38 -3,07 -27,28 -3,12 -1,20
EBIT-Margin5 12,89 12,29 11,86 -10,80 -39,57 -4,05 -1,40
Net Profit (Loss)1 0,83 0,72 1,50 -3,93 -27,38 -2,03 -2,90
Net-Margin6 4,07 3,61 7,47 -13,83 -39,72 -2,63 -3,37
Cashflow1,7 4,60 6,32 3,98 2,73 -4,49 9,15 0,00
Earnings per share8 0,20 0,18 0,37 -0,63 -1,71 -0,12 -0,16
Dividend per share8 0,16 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: PricewaterhouseCoopers

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Vita 34
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A0BL84 DE000A0BL849 AG 72,68 Mio € 27.03.2007 Halten 9F3J899W+W5
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
0,00 27,07 0,00 -35,83 3,19 7,94 0,94
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
28.06.2024 31.05.2024 30.08.2024 22.11.2024 30.04.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+2,49%
4,12 €
ATH 18,82 €
-4,19% -8,57% -21,37% -19,22% -72,53%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL